Associations - MAP2K2 (Mitogen-activated protein kinase kinase 2)

MAP2K2 mutation + TMB-H	Melanoma	MAP2K2 mutation + TMB-H	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
MAP2K2 C125S	Melanoma	MAP2K2 C125S	Melanoma	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3
MAP2K2 Q60P	Melanoma	MAP2K2 Q60P	Melanoma	trametinib + dabrafenib Resistant: C3 – Early Trials trametinib + dabrafenib Resistant : C3	trametinib + dabrafenib Resistant: C3 – Early Trials trametinib + dabrafenib Resistant : C3
MAP2K2 C125S	Melanoma	MAP2K2 C125S	Melanoma	trametinib + dabrafenib Resistant: C3 – Early Trials trametinib + dabrafenib Resistant : C3	trametinib + dabrafenib Resistant: C3 – Early Trials trametinib + dabrafenib Resistant : C3
MAP2K2 L46F	Melanoma	MAP2K2 L46F	Melanoma	trametinib Resistant: C3 – Early Trials trametinib Resistant : C3	trametinib Resistant: C3 – Early Trials trametinib Resistant : C3
MAP2K2 C125S	Melanoma	MAP2K2 C125S	Melanoma	trametinib Resistant: C3 – Early Trials trametinib Resistant : C3	trametinib Resistant: C3 – Early Trials trametinib Resistant : C3
MAP2K2 N126D	Melanoma	MAP2K2 N126D	Melanoma	trametinib Resistant: C3 – Early Trials trametinib Resistant : C3	trametinib Resistant: C3 – Early Trials trametinib Resistant : C3
MAP2K2 L46F	Melanoma	MAP2K2 L46F	Melanoma	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3
MAP2K2 N126D	Melanoma	MAP2K2 N126D	Melanoma	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3
MAP2K2 V35M	Melanoma	MAP2K2 V35M	Melanoma	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3
MAP2K2 mutation	Melanoma	MAP2K2 mutation	Melanoma	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3
MAP2K2 mutation	Pancreatic Ductal Adenocarcinoma	MAP2K2 mutation	Pancreatic Ductal Adenocarcinoma	avelumab + binimetinib Sensitive: C3 – Early Trials avelumab + binimetinib Sensitive : C3	avelumab + binimetinib Sensitive: C3 – Early Trials avelumab + binimetinib Sensitive : C3

MAP2K2 (Mitogen-activated protein kinase kinase 2)

Associations(18)

Associations
(18)